Not Yet RecruitingPhase 2ACTRN12608000241336

Asphelia Trichuris Suis Ova in Moderately Active Crohn's Disease

A Randomized, Double-Blind, Placebo-Controlled, Trial Of Asp1002 (Trichuris Suis Ova [Tso]) Therapy For Moderately Active Crohn’s Disease


Sponsor

Asphelia Pharmaceuticals Inc.

Enrollment

60 participants

Start Date

Jun 30, 2008

Study Type

Interventional

Conditions

Summary

Inflammatory bowel disease (IBD) is a chronic, relapsing condition of the gastrointestinal (GI) tract. IBD is thought to result from inappropriate T cell activation due to a combination of genetic and environmental factors. This leads to a deregulated immune response and characteristic inflammation. Crohn’s disease (CD) is a form of IBD. One theory suggests that underexposure to helminths is a major environmental factor in predisposing to CD. This “hygiene hypothesis” is based on epidemiologic findings of an inverse relationship between IBD incidence and helminthic colonization. In the proposed study, the pig whipworm Trichuris suis (T. suis), formulated as ASP1002 [Trichuris suis Ova (TSO)], a suspension for oral administration, will be administered in the clinic as a single dose for 6 times. T. suis is similar morphologically to the human whipworm but is cleared too rapidly from the human host to establish infection. Therefore, it has potential for being a natural immune modulator without significant risk of causing disease in humans. The expected duration of study participation is approximately 26 to 27 weeks, including up to 2 - 3 weeks screening, a 12 week treatment period and a follow-up visit at Week 24.


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 70 Yearss

Plain Language Summary

Simplified for easier understanding

This study is looking at asphelia Trichuris Suis Ova in Moderately Active Crohn's Disease. It is open to both men and women, aged 18 to 70, who 1. diagnosis of cd involving the ileum, colon, or ileum and colon of. People with certain health conditions such as 1. patients whose cd was diagnosed more than 5 years ago may not be able to join. If you take part, the research team will explain what is involved and monitor your health throughout the study.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

15ml(167eggs/ml) oral Asp1002 (Trichuris Suis Ova [Tso]) taken every fortnight for 12 weeks.

15ml(167eggs/ml) oral Asp1002 (Trichuris Suis Ova [Tso]) taken every fortnight for 12 weeks.


Locations(1)

New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12608000241336


Related Trials